Skip to main content
Clinical Trials/PACTR202307876581314
PACTR202307876581314
Not yet recruiting
Phase 4

Postpartum IV Iron to Treat Iron Deficiency Anemia Post Delivery (PRIORITY TRIAL). A Randomized Controlled Trial Of The Global Network For Women's and Children's Health Research Version 0.7 December 14, 2021

ational Institute of Child Health and Development0 sites600 target enrollmentJuly 6, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Haematological Disorders
Sponsor
ational Institute of Child Health and Development
Enrollment
600
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
ational Institute of Child Health and Development

Eligibility Criteria

Inclusion Criteria

  • Established pregnancy \>20 wk gestation by LMP and/or clinical assessment and/ Or USG
  • Age: 15 years (or lower limit age eligible\*) to 49 years
  • Confirmed moderate anemia (Hb 7\.0 to 9\.9 g/dL, 6\-48 hr after delivery based on a venous
  • blood sample on Hemocue®)
  • Deliver in participating study hospital or health facility
  • Able to provide informed consent
  • Plans to remain in study area for duration of the study

Exclusion Criteria

  • IV Iron infusion already received in past 3 weeks
  • Contraindication to iron supplementation (some examples may include hemolytic
  • anemia, allergy, severe infection)
  • Blood transfusion already received or scheduled in the current hospital admission
  • Known diagnosis of pre\-existing depression or other psychiatric illness
  • Stillbirth, major congenital anomaly, or neonatal loss prior to randomization
  • Women testing positive and previously untreated for malaria
  • Presenting with symptomatic anemia with dyspnea or fatigue and need for immediate
  • Women with known hemoglobinopathy (sickle cell disease or thalassemia)
  • Presence of severe allergic conditions such as severe asthma or known drug allergies

Outcomes

Primary Outcomes

Not specified

Similar Trials